AKBA Q2 2020 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$366M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$90M-10.6% YoY

Gross Profit

-$84M-93.7% margin

Operating Income

-$174M-192.8% margin

Net Income

-$176M-195.0% margin

EPS (Diluted)

$-1.28

QoQ Revenue Growth

+1.9%

Cash Flow

Operating Cash Flow

$37M

Free Cash Flow

$37M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$745M

Total Liabilities

$375M

Stockholders' Equity

$370M

Cash & Equivalents

$245M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$90M	$101M	-10.6%
Gross Profit	-$84M	$63M	-233.8%
Operating Income	-$174M	-$60M	-192.0%
Net Income	-$176M	-$58M	-202.1%

Revenue Segments

License Collaboration And Other Revenue

$59M66%

Product

$31M34%